Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin

Cancer Research

Volumn 66, Issue 16, 2006, Pages 8155-8162

  Herrero, Ana B ^a   Martín Castellanos, Cristina ^a   Marco, Esther ^b   Gago, Federico ^b   Moreno, Sergio ^a  

^a Salamanca Spain   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; FLAP ENDONUCLEASE; FUNGAL PROTEIN; PROTEIN RAD13; TRABECTEDIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA DAMAGE; DNA RECOMBINATION; DNA REPAIR; DRUG MECHANISM; ENZYME ACTIVITY; EXCISION REPAIR; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; SCHIZOSACCHAROMYCES POMBE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL CYCLE; CELL NUCLEUS; DIOXOLES; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; INTERPHASE; METHYL METHANESULFONATE; RECOMBINATION, GENETIC; S PHASE; SCHIZOSACCHAROMYCES; TETRAHYDROISOQUINOLINES;

EID: 33748035692     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0179     Document Type: Article

References (44)

1. D'Incalci M, Erba E, Damia G, et al. Unique features of the mode of action of ET-743. Oncologist 2002;7:210-6.
2. Demetri GD. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs 2002;13:S7-9.
3. D'Incalci M, Jimeno J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin Investig Drugs 2003;12:1843-53.
4. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-84.
5. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-9.
6. Moore SF II, Hurley LH. NMR-based model of an ecteinascidin 743-DNA adduct. Am Chem Soc 1997;119:5475-6.
7. Damia G, Silvestri S, Carrassa L, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 2001;92:583-8.
8. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105.
9. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
10. Moreno S, Klar A, Nurse P. Molecular genetic analysis of fission yeast Schizosaccharomyces pombe. Methods Enzymol 1991;194:795-823.
11. Foiani M, Marini F, Gamba D, Lucchini G, Plevani P. The B subunit of the DNA polymerase α-primase complex in Saccharomyces cerevisiae executes an essential function at the initial stage of DNA replication. Mol Cell Biol 1994;14:923-33.
12. Zewail-Foote M, Hurley LH. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-7.
13. Carr AM. DNA structure dependent checkpoints as regulators of DNA repair. DNA Repair (Amst) 2002;1:983-94.
14. Lindsay HD, Griffiths DJ, Edwards RJ, et al. S-phase-specific activation of Cds1 kinase defines a subpathway of the checkpoint response in Schizosaccharomyces pombe. Genes Dev 1998;12:382-95.
15. Capasso H, Palermo C, Wan S, et al. Phosphorylation activates Chk1 and is required for checkpoint-mediated cell cycle arrest. J Cell Sci 2002;115:4555-64.
16. Lambert S, Mason SJ, Barber LJ, et al. Schizosaccharomyces pombe checkpoint response to DNA interstrand cross-links. Mol Cell Biol 2003;23:4728-37.
17. Soares DG, Poletto NP, Bonatto D, Salvador M, Schwartsmann G, Henriques JA. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem Pharmacol 2005;70:59-69.
18. de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev 1999;13:768-85.
19. Alleva JL, Zuo S, Hurwitz J, Doetsch PW. In vitro reconstitution of the Schizosaccharomyces pombe alternative excision repair pathway. Biochemistry 2000;39:2659-66.
20. Baumann P, Benson FE, West SC. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 1996;7:757-66.
21. van den Bosch M, Zonneveld JB, Vreeken K, de Vries FA, Lohman PH, Pastink A. Differential expression and requirements for Schizosaccharomyces pombe RAD52 homologs in DNA repair and recombination. Nucleic Acids Res 2002;30:1316-24.
22. Muris DF, Vreeken K, Carr AM, et al. Isolation of the Schizosaccharomyces pombe RAD54 homologue, rhp54+, a gene involved in the repair of radiation damage and replication fidelity. J Cell Sci 1996;109:73-81.
23. Van Komen S, Petukhova G, Sigurdsson S, Stratton S, Sung P. Superhelicity-driven homologous DNA pairing by yeast recombination factors Rad51 and Rad54. Mol Cell 2000;6:563-72.
24. Lieber MR. The FEN-1 family of structure-specific nucleates in eukaryotic DNA replication, recombination and repair. Bioessays 1997;19:233-40.
25. Shen B, Nolan JP, Sklar LA, Park MS. Functional analysis of point mutations in human flap endonuclease-1 active site. Nucleic Acids Res 1997;25:3332-8.
26. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function of XPG protein during dual incision in human nucleotide excision repair. J Biol Chem 1997;272:16030-4.
27. Xiao W, Chow BL. Synergism between yeast nucleotide and base excision repair pathways in the protection against DNA methylation damage. Curr Genet 1998;33:92-9.
28. Lee SK, Yu SL, Prakash L, Prakash S. Requirement of yeast RAD2, a homolog of human XPG gene, for efficient RNA polymerase II transcription, implications for Cockayne syndrome. Cell 2002;109:823-34.
29. Shiomi N, Kito S, Oyama M, et al. Identification of the XPG region that causes the onset of Cockayne syndrome by using Xpg mutant mice generated by the cDNA-mediated knock-in method. Mol Cell Biol 2004;24: 3712-9.
30. Knauf JA, Pendergrass SH, Marrone BL, Strniste GF, MacInnes MA, Park MS. Multiple nuclear localization signals in XPG nuclease. Mutat Res 1996;363:67-75.
31. Gary R, Ludwig DL, Cornelius HL, MacInnes MA, Park MS. The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21. J Biol Chem 1997;272:24522-9.
32. Chapados BR, Hosfield DJ, Han S, et al. Structural basis for FEN-1 substrate specificity and PCNA-mediated activation in DNA replication and repair. Cell 2004;116:39-50.
33. Broggini M, Coley HM, Mongelli N, et al. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 1995;23:81-7.
34. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002;277:41580-9.
35. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 2000;97:6780-4.
36. Beljanski V, Marzilli LG, Doetsch PW. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 2004;65:1496-506.
37. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002;62:4899-902.
38. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 2001;8:1033-49.
39. Buterin T, Hess MT, Gunz D, Geacintov NE, Mullenders LH, Naegeli H. Trapping of DNA nucleotide excision repair factors by nonrepairable carcinogen adducts. Cancer Res 2002;62:4229-35.
40. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003;4:435-45.
41. Tercero JA, Diffley JF. Regulation of DNA replication fork progression through damaged DNA by the Mec1/Rad53 checkpoint. Nature 2001;412:553-7.
42. Lopes M, Cotta-Ramusino C, Pellicioli A, et al. The DNA replication checkpoint response stabilizes stalled replication forks. Nature 2001;412:557-61.
43. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005;25:7158-69.
44. Memisoglu A, Samson L. Contribution of base excision repair, nucleotide excision repair, and DNA recombination to alkylation resistance of the fission yeast Schizosaccharomyces pombe. J Bacteriol 2000;182:2104-12.